

1 T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ
2 between disease-modifying therapies

3 Asia-Sophia Wolf*¹, Anthony Ravussin*¹, Marton König*², Mathias H. Øverås², Guri Solum¹,
4 Ingrid Fadum Kjøenstad¹, Adity Chopra^{3,4}, Trygve Holmøy^{3,5}, Hanne F. Harbo^{2,3}, Silje
5 Watterdal Syversen⁶, Kristin Kaasen Jørgensen⁷, Einar August Høgestøl^{2,8}, Jon Torgils
6 Vaage^{3,4}, Elisabeth G. Celius^{2,3}, Fridtjof Lund-Johansen^{3,4}, Ludvig A. Munthe^{3,4,9}, Gro Owren
7 Nygaard^{†2}, Siri Mjaaland^{†1}

8 * Joint first authors

9 † Joint last authors

10

11 ¹ Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health,
12 Oslo, Norway

13 ² Department of Neurology, Oslo University Hospital, Oslo, Norway

14 ³ Institute of Clinical Medicine, University of Oslo, Oslo, Norway

15 ⁴ Department of Immunology, Oslo University Hospital, Oslo, Norway

16 ⁵ Department of Neurology, Akershus University Hospital, Lørenskog, Norway

17 ⁶ Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY),
18 Diakonhjemmet Hospital, Oslo, Norway

19 ⁷ Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway

20 ⁸ Department of Psychology, University of Oslo

21 ⁹ KG Jebsen Centre for B cell malignancy, University of Oslo, Oslo, Norway

22

23 Corresponding author: Marton König, Department of Neurology, Oslo University Hospital, PO
24 Box 4956, Nydalen, N-0424 Oslo, Norway (makoni@ous-hf.no).

25

26 Conflicts of interest

27 MK reported receiving speaker honoraria from Novartis, Biogen, Merck and Sanofi outside
28 the submitted work.

29 TH has received speaker honoraria from Biogen, Merck, Novartis, Sanofi, Bristol Myers
30 Squibb and Roche, and participated in clinical trials organized by Roche, Merck and Biogen

31 EAH received honoraria for lecturing and advisory board activity from Biogen, Merck and
32 Sanofi-Genzyme and unrestricted research grant from Merck.

33 EGC has participated in advisory boards and received speaker honoraria from Biogen,
34 Janssen, Merck, Novartis, Teva, Roche, Sanofi and Bristol Myers Squibb.

35 KKJ has received speaker bureaus from Bristol Myers Squibb and Roche.

36

37 Key words: multiple sclerosis, vaccination, SARS-CoV-2, T cells, immunocompromised

38 Abstract

39 Immune responses in people with multiple sclerosis (pwMS) on disease-modifying therapies
40 (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-
41 targeting immunotherapies including anti-CD20 treatments and sphingosine-1-phosphate
42 receptor (S1PR) modulators attenuate antibody responses after vaccination. Evaluation of
43 cellular responses after vaccination is therefore of particular importance in these populations.
44 In this study, we analysed CD4 and CD8 T cell functional responses to SARS-CoV-2 spike
45 peptides in healthy controls and pwMS on five different DMTs by flow cytometry. Although
46 pwMS on anti-CD20 and S1PR therapies had low antibody responses after both 2 and 3
47 vaccine doses, T cell responses in pwMS on anti-CD20 therapies were preserved after a
48 third vaccination, even when additional anti-CD20 treatment was administered between
49 vaccine doses 2 and 3. PwMS taking S1PR modulators had low detectable T cell responses
50 in peripheral blood. CD4 and CD8 T cell responses to SARS-CoV-2 variants of concern Delta
51 and Omicron were lower than to the ancestral Wuhan-Hu-1 variant. Our results indicate the
52 importance of assessing both cellular and humoral responses after vaccination and suggest
53 that even in the absence of robust antibody responses vaccination can generate immune
54 responses in pwMS.

55 Introduction

56 Immune responses to SARS-CoV-2 in immunocompromised individuals have been of intense
57 interest throughout the COVID-19 pandemic. In the absence of vaccination, immunologically
58 vulnerable groups are especially susceptible to severe COVID-19 disease and hospitalisation
59 (reviewed in (1)); after vaccination, reduced responses to SARS-CoV-2 vaccines and
60 potential vaccine failure have been of particular concern.

61 Multiple sclerosis (MS) is an immune-mediated disease characterised by inflammation and
62 demyelination in the central nervous system. Current treatment involves modulation of the
63 immune system to alleviate inflammation. However, some disease-modifying therapies
64 (DMTs) can also impede an effective response to infectious diseases and vaccination
65 (reviewed in (2)). It is unclear whether people with MS (pwMS) are more susceptible to
66 severe COVID-19 disease in the absence of vaccination (3-6); current evidence suggests
67 that this varies depending on DMT usage, where treatment with anti-CD20 drugs presents an
68 increased risk factor (7, 8), as well as neurological disability, comorbidities, and age (6, 8). It
69 is therefore important to establish vaccine effectiveness in pwMS and whether vaccination
70 protects against COVID-19 disease to the same extent as in the general population. Certain
71 DMTs are known to be associated with increased risk of other infections: anti-CD20 drugs
72 such as rituximab, ocrelizumab, and ofatumumab are associated with a range of serious
73 infections, including respiratory tract infections (9, 10); sphingosine-1-phosphate receptor
74 (S1PR) modulators, including fingolimod, ozanimod, and siponimod, which sequester
75 lymphocytes in lymph nodes, are associated with increased risk of herpesvirus infections or
76 reactivations (11); and natalizumab, an anti-alpha-4 integrin monoclonal antibody (mAb), with
77 a risk of progressive multifocal leukoencephalopathy (9).

78 The primary focus of many vaccine efficacy studies to date has been the humoral immune
79 response (12, 13). Many DMTs, particularly anti-CD20 drugs, target B cells and people on
80 such treatments have reduced or non-existent antibody responses after vaccination (14-18);
81 pwMS on fingolimod have been found to have significantly reduced antibody responses (14,

82 19). By contrast, pwMS taking other DMTs including natalizumab (20, 21), cladribine (an
83 adenosine mimic which triggers lymphocyte apoptosis) (22), and alemtuzumab (an anti-
84 CD52 mAb that depletes T and B cells) (23) appear to have antibody responses comparable
85 to untreated control groups.

86 Nevertheless, it is unclear if vaccine-specific T cell responses are impaired. Several studies
87 have looked at cellular responses to SARS-CoV-2 spike peptides in pwMS after two doses of
88 SARS-CoV-2 vaccine (16, 21, 24-26) and found that IFN- γ + T cell responses were
89 detectable in many, though not all, patients on a variety of DMTs. One exception was pwMS
90 treated with fingolimod (26), where T cell responses were significantly attenuated. Although
91 not all individuals on anti-CD20 therapies developed T cell responses, it further appears that
92 T cell responses and antibody titres are not well correlated, and so a lack of antibody
93 response is not in itself indicative of a failed response to vaccination (27). Additionally, data
94 on the effect of a third vaccine dose on both antibody levels and T cell responses are mixed;
95 some studies suggest no effect of additional vaccination on either humoral or cellular
96 immune responses (28), whereas others find boosted responses (29, 30).

97 The time period between receiving a dose of DMT and vaccination varies between DMTs.
98 Fingolimod, for example, is taken daily, whereas anti-CD20 treatments are administered at
99 six-month intervals, with a clear impact of this interval on the humoral response. An
100 increased gap between administration of anti-CD20 therapies and vaccination is associated
101 with stronger antibody responses (15, 27, 31, 32), which may be beneficial during
102 vaccination but can also lead to interruptions in ongoing treatment of MS or undesirable
103 delay in vaccine schedules. It is therefore of interest to establish what effect ongoing DMT
104 treatment has on vaccine responsiveness during both the primary vaccine course and for
105 subsequent boosters.

106 Recent register studies indicate that pwMS treated with high efficacy DMTs, including
107 alemtuzumab, natalizumab, cladribine, S1PR modulators, and anti-CD20 therapies, have the
108 best long-term outcomes for reduced worsening of disability and relapse outcomes (33, 34).

109 Although for safety reasons alemtuzumab is rarely given to newly diagnosed patients, many
110 people have been treated with this induction therapy during the last decade and comprise an
111 important subset of pwMS. This study therefore focused on the cellular response to these
112 five therapies that are among the most likely to be the treatments of choice for future pwMS.
113 The aim of this study was to investigate IgG antibody binding to the receptor binding domain
114 (RBD) on the spike protein of SARS-CoV-2 as well as functional spike-specific CD4 and CD8
115 T cell responses from pwMS on five different DMTs and a healthy control group after two
116 doses of SARS-CoV-2 vaccine. We also investigated whether a third vaccine dose improved
117 the humoral and/or cellular responses in individuals treated with rituximab or fingolimod who
118 had impaired IgG anti-spike RBD antibody responses after two vaccine doses.

119

120 Results

121 A cohort of pwMS living in Oslo or Akershus, Norway, who were treated with DMTs prior to
122 the beginning of the COVID-19 pandemic were recruited as part of an ongoing population-
123 based study of vaccine responses in pwMS in Norway (NevroVax) (15, 29). Cellular samples
124 were collected from a subset of individuals on different DMTs (fingolimod, rituximab,
125 cladribine, natalizumab and alemtuzumab) both before and after the primary course of 2
126 vaccine doses in April-July 2021 (Supplementary Figure 1). Healthy controls were recruited
127 from among healthcare workers at Diakonhjemmet Hospital and Akershus University
128 Hospital. Rituximab- and fingolimod-treated individuals who had low antibody responses after
129 vaccination were offered a 3rd vaccine dose in the summer of 2021 (EudraCT Number: 2021-
130 003618-37, see Methods), before recommendations for booster vaccines in Norway were
131 changed in September of that year to recommend a 3rd dose for all immunocompromised
132 individuals. The characteristics of this cohort are described in Table 1 according to DMT,
133 including age, sex, time since last drug administration, and vaccine type (primarily the mRNA
134 vaccines BNT162b2 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 (Spikevax, Moderna);

135 see Methods for further details). Breakthrough COVID-19 infections >14 days after
136 vaccination are shown for each group (n=29 across all DMTs and healthy controls).
137 Infections were predominantly contracted between November 2021-February 2022,
138 representing a mixture of Delta and Omicron VOC infections. None of the individuals were
139 hospitalised or died.

140 DMTs vary based on mechanism of action and cellular target. We therefore assessed the
141 effect of each DMT on the lymphocyte, CD4 and CD8 T cell frequency and function by flow
142 cytometry (Figure 1). The full flow cytometry gating strategy is shown in Supplementary
143 Figure 2. Compared to healthy controls, pwMS on DMTs did not show altered frequencies of
144 CD3+ lymphocytes except for fingolimod-treated individuals, who had significant reductions
145 in the CD3+ cell populations (Figure 1A) (proportion of CD3+ live lymphocytes in fingolimod-
146 treated: median, 46.9%; IQR, 44.9%; healthy controls: median, 66.8%; IQR, 11%).
147 Additionally, fingolimod-treated individuals had sharply reduced CD4+ T cell populations
148 (fingolimod-treated: median, 19.2%; IQR, 26.0%; healthy controls: median, 63.1%; IQR,
149 14.1%) and a concomitant increase in CD8+ T cells (Figure 1B and Supplementary Figure 3).
150 The graphs show frequencies from the post-vaccination time point; however, the cell
151 population frequencies for individuals were consistent before and after vaccination. The
152 CD4:CD8 T cell ratio did not correlate with antibody responses in fingolimod-treated
153 individuals, and people with less distorted ratios of T cells did not have improved antibody
154 titres, which were low throughout the group (data not shown).

155 Antibody and T cell responses were measured to assess the immune response to two doses
156 of vaccine. Samples taken 3 weeks (median 20.5 days) after the 2nd vaccine dose were
157 assayed for antibody binding activity (Figure 1C). IgG anti-spike RBD responses were
158 classified as negative (<5 BAU/ml), very weak positive (5-20 BAU/ml), weak positive (20-200
159 BAU/ml), and positive (>200 BAU/ml) and are indicated on the graph for reference. All
160 healthy controls and individuals treated with alemtuzumab, cladribine and natalizumab had
161 strong antibody titres, predominantly in the 'positive' range (median per group: healthy

162 control, 1166 BAU/ml; alemtuzumab, 5591 BAU/ml; cladribine, 3081 BAU/ml; natalizumab,
163 3625 BAU/ml). However, individuals treated with fingolimod or rituximab had poor antibody
164 responses after two vaccine doses (median: fingolimod, 2.5 BAU/ml; rituximab, 0.5 BAU/ml
165 (below the level of detection for this assay)).

166 T cell responses were assessed using activation-induced marker (AIM) assays and
167 measured by flow cytometry (see Supplementary Figure. 2 for gating). Peripheral blood
168 mononuclear cells (PBMCs) were stimulated with SARS-CoV-2 spike peptides and CD4 T
169 cell activation was measured by CD40L and TNF- α coexpression (Figure 1D) before (V0,
170 baseline) and 2 weeks after (V2) vaccination. Samples were taken from the same individuals
171 at both time points wherever possible, indicated by paired dots. There was a significant
172 increase in the spike-specific CD4 T cell response after vaccination in the healthy controls
173 and alemtuzumab-treated patients. This suggested that most of the alemtuzumab-treated
174 pwMS had reconstituted their immune system within the time since last treatment, which was
175 more than three years for most patients. Responses were highly heterogeneous and did not
176 reach statistical significance in the other DMT groups. More than half (10/18) of the
177 fingolimod-treated group had too few CD4 T cells in our assay to accurately measure
178 activation responses and were excluded from the analysis as we had too few CD4+ events to
179 calculate the percent response. CD8 T cell responses (Figure 1E) producing IFN- γ and TNF-
180 α varied between individuals. Of interest, IFN- γ + and TNF- α + spike-specific CD8+ T cell
181 responses from fingolimod-treated individuals negatively correlated with higher proportions of
182 CD8+ T cells (i.e. individuals with more skewed CD4/CD8 ratios also had fewer cytokine
183 producing CD8 T cells), although this did not reach statistical significance (Supplementary
184 Figure 3I).

185 As the fingolimod- and rituximab-treated individuals had poor antibody responses, these
186 patients received a third dose of vaccine (see Methods) (Figure 2). Individuals treated with
187 rituximab did not show significant improvements in IgG anti-spike RBD after a third vaccine
188 dose (Figure 2A), although the overall responses and number of responders increased

189 (median and IQR at V2, 1.3 and 18.3 BAU/ml; at V3, 2.0 and 665.5 BAU/ml; 13/43 (30.2%)
190 individuals had >5 BAU/ml titres after 2 vaccine doses, increasing to 27/61 (44.3%) after 3
191 vaccine doses), suggesting that some, though not all, individuals improved their antibody
192 responses after repeated vaccination. However, the number of patients that were positive
193 (>200 BAU/ml) was significantly increased from 5/43 after 2 doses to 19/61 after 3 doses
194 (two-tailed $p=0.0320$, Fisher's exact test). Moreover, a significant proportion of individuals
195 had detectable spike-specific CD4 and CD8 T cell responses (Figure 2B-C), demonstrating
196 that rituximab treatment does not inhibit T cell responses to the same extent as antibody
197 responses.

198 The same effect was not seen for people treated with fingolimod. After a third vaccine dose,
199 fingolimod-treated patients showed no significant increase in IgG anti-spike RBD (Figure 2D),
200 and generally had even lower antibody responses than the rituximab-treated group, with no
201 patients reaching the 'positive' response classification of >200 BAU/ml (median and IQR at
202 V2, 2.1 and 5.35 BAU/ml; at V3, 8.0 and 33.5 BAU/ml). Despite an increase in weak
203 responders (20-200 BAU/ml), this was not statistically significant (1/13 individuals had weak
204 responses after V2 compared to 7/21 after V3; two-tailed $p=0.1164$, Fisher's exact test).
205 Spike-specific CD4 and CD8 responses also showed no significant response, suggesting
206 that fingolimod has a major impact on measurable T cell responses in blood as well as
207 antibody levels. We did see a small but statistically significant CD8 T cell response
208 ($p=0.0429$) to influenza (flu) peptides compared to the unstimulated control, suggesting that
209 existing T cell responses, possibly generated prior to beginning fingolimod treatment, are
210 maintained over time.

211 61.4% (51/83) of fingolimod- or rituximab-treated patients received an influenza vaccine
212 between September 2020 and February 2021. However, influenza-specific T cell responses
213 did not significantly differ between individuals who had received a seasonal influenza
214 vaccination during the previous winter (2020-21) and those who had not. This suggested that
215 T cell responses generated via previous vaccination or influenza infections prior to the

216 COVID-19 pandemic were still detectable in these patients. There was a weak but significant
217 positive correlation between CD4 responses to SARS-CoV-2 spike and CD4 responses to
218 influenza peptides in rituximab-treated patients, suggesting individual differences to vaccine
219 antigens in general (Supplementary Figure 4A). T cell responses to EBV and CMV peptides
220 were higher than responses to the vaccine peptides, which represents the difference
221 between vaccination and latent viral infection. In rituximab-treated individuals we saw strong
222 CMV-specific CD4 and CD8 T cell responses ($p=0.0005$ and $p<0.0001$ respectively,
223 Wilcoxon tests) (Figure 2B) and EBV-specific CD8 T cell responses ($p<0.0001$) (Figure 2C).
224 However, there was no correlation between CD4 T cell responses to spike and CMV in
225 rituximab-treated patients, (Supplementary Figure 4B), CD4 and CD8 T cell responses to
226 spike (Supplementary Figure 4C), or CD4 responses and antibody responses
227 (Supplementary Figure 4D), consistent with other studies showing low concordance between
228 these measures of immune responsiveness (27).

229 The administration interval of DMTs varies by drug, as described in Table 1. In the course of
230 this study, patients taking rituximab received treatment according to their individual
231 schedules. All patients received rituximab prior to the baseline (V0) sample and completed
232 the initial two-dose vaccine course without further rituximab infusions. Between the second
233 and third vaccine doses, approximately half (30/62) of the patients received another dose of
234 rituximab (median time 8.43 weeks before V3, range 1.86-19.7 weeks). We hypothesised
235 that this rituximab dosage impaired the ability to respond to vaccination. Antibody and T cell
236 responses in these two groups were therefore compared (Figure 3). There was no significant
237 difference in IgG anti-spike RBD between these two groups after the second vaccine dose
238 (V2), but after a third vaccine dose (V3) individuals who had recently received rituximab had
239 significantly lower antibody activity (Figure 3A) than those who had not ($p=0.023$, unpaired t
240 test). However, there was no such difference between the T cell responses of the two groups
241 (Figure 3B-C). Comparing the spike-specific responses between groups showed no
242 difference in CD4 ($p=0.998$, unpaired t test) or CD8 T cell activation ($p=0.545$), suggesting

243 that T cell responses are not affected by re-administration of rituximab after the primary
244 vaccine course.

245 Finally, the question of whether vaccination confers protection against SARS-CoV-2 variants
246 of concern (VOC) has been of particular concern since the initial emergence of the Alpha
247 (B.1.1.7) variant and subsequent Delta (B.1.617.2) and Omicron (B.1.1.529/BA.1-5) variants.
248 Mutations in the spike region of these variants are thought to reduce the ability of vaccine-
249 generated antibodies to recognise these variants and potentially to reduce protection against
250 them. To measure how T cell responses from vaccination were affected, we assessed CD4
251 and CD8 T cell responses to the mutated peptides of these three variants (Figure 4). PBMCs
252 from triple-vaccinated rituximab-treated patients were stimulated as before with only the
253 mutated peptide regions from the Alpha, Delta, or Omicron variants, as well as the
254 homologous peptides for each variant from the original Wuhan-Hu-1 sequence). The location
255 and number of mutated peptides (34, 32 and 83 peptides for Alpha, Delta, and Omicron
256 respectively) are shown in Figure 4A. There were no significant differences in CD4 T cell
257 responses to the Alpha variant compared to the homologous Wuhan-Hu-1 sequence, but
258 significantly reduced responsiveness to the mutated peptides of both the Delta ($p=0.047$,
259 Wilcoxon t test) and Omicron variants ($p=0.0028$) (Figure 4B). Although CD8 T cell
260 responses were reduced, particularly for the Delta VOC, these differences did not reach
261 significance (Figure 4C).

262

263 Discussion

264 Older and immunocompromised individuals are particularly at risk of severe COVID-19
265 disease. Vaccine efficacy in immunocompromised individuals is therefore important to
266 understand, particularly as many countries including Norway (35) have achieved high
267 vaccine coverage and have since lifted many or all infection-limiting measures such as social
268 distancing. However, SARS-CoV-2 variants continue to circulate and vulnerable groups may

269 still be at risk of severe disease. These data show that pwMS treated with alemtuzumab,
270 cladribine, and natalizumab have robust humoral and CD4 and CD8 T cell responses after
271 two vaccine doses, in agreement with other studies (3, 14, 20, 22, 25). However, individuals
272 treated with fingolimod and rituximab have strongly reduced antibody responses compared
273 with both healthy controls and pwMS taking other DMTs. Upon receipt of a third vaccine
274 dose, both treatment groups showed small increases in IgG anti-spike levels and a
275 significantly increased percentage of patients developed high responses (>200 BAU/ml) in
276 the rituximab treated group, demonstrating that some individuals were capable of increasing
277 B cell responses. This finding was also found in a larger study where improved IgG anti-spike
278 responses were found after third vaccination (29). Moreover, triple-vaccinated rituximab-
279 treated individuals demonstrated both CD4 and CD8 T cell responses against SARS-CoV-2
280 spike peptides. These T cell responses were not reduced even when individuals received
281 rituximab between their second and third vaccine doses, suggesting that although re-
282 administration of anti-CD20 drugs does impair humoral responses, cellular responses are
283 preserved.

284 Additionally, we observed strong CD4 and CD8 T cell responses to the herpesviruses CMV
285 and EBV in pwMS, suggesting that specific T cell responses against antigens from long-term
286 latent infections are present. T cell activation against other vaccine antigens such as
287 influenza were comparable to the SARS-CoV-2 spike-specific responses, and rituximab-
288 treated individuals showed a positive correlation between spike-specific and flu-specific
289 responses. This suggests that vaccine responsiveness varies by individual but is not
290 necessarily associated with T cell responses to other infections such as CMV. Immune
291 responses may also differ based on whether individuals were already using DMTs at the time
292 of antigen exposure, which may affect the magnitude of the immune response, as well as the
293 availability and duration of antigen seen during vaccination or acute infection compared to
294 chronic infections.

295 In pwMS treated with fingolimod, a third vaccine dose did not appear to improve either the
296 antibody or T cell responses. As fingolimod is taken daily, the fluctuations in B cell counts
297 seen in individuals taking anti-CD20 drugs are not seen (36). The reduction in peripheral
298 lymphocyte and CD4 T cell counts we observed here was consistent in individuals at
299 different sampling points, suggesting that the administration of fingolimod causes lymphocyte
300 sequestration to different extents for each individual. Although antibody titres were strongly
301 reduced for all fingolimod-treated patients, we observed that individuals with less skewed
302 CD4:CD8 T cell ratios had stronger spike-specific CD8 T cell responses, suggesting that
303 people with higher circulating CD4 T cell frequencies are more likely to generate measurable
304 and potentially protective cellular responses.

305 Nevertheless, pwMS receiving fingolimod do not appear to be at higher risk of severe
306 COVID-19 or hospitalisation than the general population prior to vaccination (7, 37).
307 Fingolimod has been found to reduce proinflammatory cytokine release from dendritic cells
308 and monocytes (38) which may reduce detrimental uncontrolled inflammation associated with
309 severe COVID-19 disease (39). Additionally, as lymphocytes are sequestered rather than
310 destroyed by S1PR modulators (40), failure to detect T cell responses in peripheral blood
311 may not fully reflect the extent of the total T cell response, and non-circulating cellular
312 responses induced by vaccination may be present in the lymph nodes or other secondary
313 lymphoid organs.

314 Several large-scale studies have found that pwMS on fingolimod or ocrelizumab are at higher
315 risk of SARS-CoV-2 infection after vaccination than the general population or pwMS on other
316 DMTs (41-43), possibly reflecting the role of circulating antibodies in preventing infection.
317 However, the severity of these infections is still unclear, and where cases could be followed
318 on an individual level, there were no deaths from COVID-19 (42, 43). Further research has
319 found that, even after vaccination, pwMS on anti-CD20 drugs were at higher risk of
320 hospitalisation but not death; this risk was not seen with other DMTs including S1PR
321 modulators (44). In our study, 29 individuals across all DMTs contracted SARS-CoV-2 after

322 vaccination and none of these were hospitalised or died. Further large-scale studies are
323 required to determine vaccine protection against severe disease and death in pwMS and
324 particularly patients treated with anti-CD20 drugs and S1PR modulators.

325 The emergence of SARS-CoV-2 VOC has further complicated the question of vaccine
326 efficacy and protection. Neutralising antibodies against the Delta and Omicron VOC have
327 been found to be sharply reduced compared to the original Wuhan-Hu-1 strain (45), while T
328 cell responses are more heterogeneous and show wide cross-reactivity to other human
329 coronaviruses as well as between variants (46-48). In triple-vaccinated rituximab-treated
330 individuals we found that CD4+ T cell responses to both the Delta and Omicron VOC were
331 reduced compared to WT, suggesting that although T cells are responsive to the mutated
332 VOC regions, vaccine-generated T cell-mediated protection may be reduced. However,
333 these mutated regions cover only a fraction of the spike peptide sequences and further work
334 is needed to determine how these mutations affect T cell vaccine responses.

335 We found no correlation between any combinations of antibody titre, CD4 T cell responses,
336 or CD8 T cell responses, and therefore using only one of these parameters as an indication
337 of immune responsiveness cannot give a full picture of vaccine efficacy. Although the
338 correlates of protection against SARS-CoV-2 infection and severe COVID-19 disease are still
339 unclear and the relative roles of antibody-mediated virus neutralisation and T cell-dependent
340 protection are still being extensively studied (49-51), analysis of cellular responses in
341 addition to antibody titres can give a better understanding of whether immunosuppressed
342 individuals are likely to require additional protective measures. Further follow up studies are
343 required to determine whether T cell responses in the absence of antibody titres, such as
344 seen in our rituximab-treated population, are protective against severe disease, but the
345 current evidence supports the contention that T cell immunity is sufficient.

346 One limitation of this work is a lack of longitudinal sampling to measure changes in CD4 and
347 CD8 T cell responses between the second and third vaccine for the rituximab- and

348 fingolimod-treated patients. The question of whether repeated vaccination with antigens from
349 the Wuhan-Hu-1 variant can prevent disease from successive VOC remains to be seen.

350 In summary, we found that pwMS on DMTs that inhibit antibody responses are still capable
351 of mounting T cell responses comparable with healthy controls, and furthermore that
352 continued administration of the widely used anti-CD20 drug rituximab between the primary
353 vaccine course and subsequent vaccine doses does not impede cellular responses. Further
354 analyses of the efficacy and durability of cellular responses, and well as the impact of
355 additional vaccination, are needed to better understand how vaccines protect against severe
356 disease in immunocompromised individuals.

357

358 Methods

359 Participant recruitment and ethical approvals

360 All patients from the Norwegian MS registry (n=12000) in 2021 were invited to participate in
361 the humoral arm of the NevroVax study. A subgroup of patients from Oslo University Hospital
362 on the DMTs alemtuzumab, cladribine, natalizumab, fingolimod and rituximab (c. n=10 per
363 DMT) were recruited to provide PBMC samples, along with all patients who lacked antibody
364 responses after 2 vaccine doses (considered at the time to be <70 arbitrary units (AU)/ml by
365 ELISA). Individuals from Oslo University Hospital, Akershus University Hospital and
366 Haukeland University hospital with low humoral responses subsequently received a third
367 vaccine dose and those treated at Oslo University Hospital or Akershus University Hospital
368 comprised the fingolimod- and rituximab-treated individuals at V3. Healthy controls were
369 recruited among healthcare workers from Diakonhjemmet Hospital and Akershus University
370 Hospital and samples were stored in the Oslo University Hospital biobank.

371 Vaccination and inclusion in vaccination trial

372 PwMS were vaccinated as per guidelines of the Norwegian Corona Vaccination Program
373 where immunocompromised individuals and healthcare workers (who participated here as
374 healthy controls) were high priority. Vaccines were administered according to the
375 manufacturers' recommendations and health administration advice at the time, ranging from
376 three weeks between first and second doses for mRNA-1273 and 6-10 weeks for BNT162b2.
377 Some individuals received first doses of ChAdOx1-S (Vaxzevria, AstraZeneca), the
378 distribution of which was subsequently discontinued in Norway in March 2021, and received
379 second doses of BNT162b2. Individuals who had a COVID-19 infection before or during the
380 course of vaccination were excluded from further analyses. Individuals who failed to
381 seroconvert to IgG anti-spike (RBD) after the standard two doses were invited to participate
382 in a vaccination trial to receive a third dose of mRNA-1273 or BNT162b2 outside the
383 framework of the Norwegian Corona Vaccination Program (EudraCT Number: 2021-003618-
384 37). Further patients included in this study after 1st September 2021 received third dose
385 vaccines following revised guidelines in the Norwegian Corona Vaccination Program (where
386 all immunocompromised adults were advised to receive a third dose).

387 Sample collection

388 Venous blood for PBMC isolation was collected at Oslo University Hospital into BD
389 Vacutainer CPT tubes with sodium citrate. Tubes were centrifuged for 20 minutes at 1600xg
390 to isolate PBMCs, which were then pipetted into fresh tubes, washed twice with RPMI, and
391 frozen in 90% foetal calf serum (FCS) (Gibco, Thermo Fisher) with 10% dimethyl sulfoxide
392 (DMSO, Sigma Aldrich) in liquid nitrogen for future use.

393 T cell stimulation and flow cytometry

394 Cryopreserved PBMCs were thawed in RPMI, washed thrice to remove residual DMSO, and
395 counted. Cells were plated into 96-well U-bottomed plates at 200,000 cells per well and
396 stimulated for 24 hours in RPMI culture media containing 10% FCS, 1mM sodium pyruvate
397 (Gibco, Thermo Fisher), 1x MEM NEAA (Gibco), 50nM 1-thioglycerol and 12ug/ml

398 gensumycin. GolgiPlug (BD Biosciences) containing brefeldin A was added after 2 hours of
399 stimulation until the end of the incubation. Cells were stimulated with peptide pools:
400 PepTivator SARS-CoV-2 Prot_S covering the immunodominant sequence domains of the
401 spike glycoprotein from the SARS-CoV-2 (Wuhan-Hu-1 variant), EBV Consensus, and CMV
402 pp65 pool (used according to the manufacturer's recommendations at 0.75nmol/ml, all
403 Miltenyi Biotec) and pooled pan-influenza peptides for HLA class I and II (final concentration
404 1µg/ml) (GenScript). Peptide pools for mutated SARS CoV-2 Spike are outlined in the next
405 paragraph. Cytostim (Miltenyi Biotec) was used as a positive control according to the
406 manufacturer's recommendation.

407 After 24 hours, cells were centrifuged at 500xg for 5 minutes, the supernatant discarded, and
408 cells resuspended in FACS buffer (1% FCS in PBS). Cells were centrifuged again and the
409 supernatant removed. Cells were incubated with 10µl surface antibody cocktail (anti-human
410 CD3-BV605 (clone SK7) (BD Biosciences), CD4-eFluor 450 (OKT-4), CD8-AF488 (OKT-8),
411 and Fixable Live/Dead Near-IR (1:1000 dilution) (all ThermoFisher)) for 30 minutes at 4°C,
412 washed in FACS buffer, then fixed in Fix/Perm (BD Biosciences) for 20 minutes at room
413 temperature. Cells were then washed twice with PermWash (BD Biosciences) and incubated
414 with 10µl intracellular antibody cocktail (anti-human IFN-γ-BV711 (clone 4S.B3), CD40L-
415 BV510 (24-31) (both BioLegend), TNF-α-PE (Mab11), CD69-APC (FN50) (both BD
416 Biosciences)) for 30 minutes at room temperature. Cells were finally washed with PermWash
417 and resuspended in 200ul FACS buffer for analysis by flow cytometry within 24 hours.

418 Cells were acquired on a BioRad ZE5 flow cytometer and analysed with FlowJo™ v.10.7
419 Software (BD Life Sciences).

420 Variants of Concern and mutated peptide sequences

421 Three PepTivator SARS-CoV-2 VOC spike protein Mutation Pools and the three
422 corresponding spike protein WT Reference Pools (all Miltenyi Biotec) were used at a final
423 concentration of 0.75 nmol/ml per the manufacturer's recommendation. Prot_S B.1.1.7

424 Mutation Pool (cat. no. 130-127-844) included 34 peptides from 10 mutations: deletion 69,
425 deletion 70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. The
426 corresponding non-mutated peptide pool control was Prot_S B.1.1.7 WT Reference Pool
427 (cat. no. 130-127-841).

428 Prot_S B.1.617.2 Mutation Pool (cat. no. 130-128-763) included 32 peptides from 10
429 mutations: T19R, G142D, E156G, deletion 157, deletion 158, L452R, T478K, D614G,
430 P681R, and D950N. This subvariant lacks the E484Q mutation. The non-mutated peptide
431 pool control was Prot_S B.1.617.2 WT Reference Pool (cat. no. 130-128-761).

432 Prot_S B.1.1.529/BA.1 Mutation Pool (cat. no. 130-129-928) included 83 peptides from 37
433 mutations: A67V, H69 deletion, V70 deletion, T95I, G142D, V143 deletion, Y144 deletion,
434 Y145 deletion, N211 deletion, L212I, insertion 214EPE, G339D, S371L, S373P, S375F,
435 K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H,
436 T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
437 The non-mutated peptide pool control was Prot_S B.1.1.529/BA.1 WT Reference Pool (cat.
438 no. 130-129-927).

439 Antibody quantification

440 Semiquantitative measurement of antibodies to full-length spike protein (Spike-FL) and the
441 receptor-binding domain (RBD) from SARS-CoV-2 was performed using a multiplexed bead-
442 based assay as described in (52). Polymer beads with fluorescent barcodes were coupled to
443 successively to neutravidin (ThermoFisher) and biotinylated viral antigens to generate bead-
444 based protein arrays. Sera were diluted 1:100 in assay buffer (PBS, 1% Tween-20, 10ug/ml
445 D-biotin, 10 µg/ml neutravidin, 0.1% sodium azide). Diluted sera were incubated with bead-
446 based arrays in 384 well plates for 30 minutes at 22°C at constant agitation, washed three
447 times in PBS/1% Tween-20 (PBT) and labelled with R-Phycoerythrin (R-PE)-conjugated
448 goat-anti-human IgG (Jackson ImmunoResearch). For measurement of neutralizing
449 antibodies, the beads were pelleted after incubation with serum and labelled successively

450 with digoxigenin-conjugated human ACE2 and mouse monoclonal anti-digoxigenin (Jackson
451 Immunoresearch), which was conjugated in-house to R-PE. The beads were analyzed with
452 an AttuneNxT flow cytometer (ThermoFisher), and raw data (fcs.3.1) were analyzed in
453 WinList 3D (Verity Softwarehouse). The median R-PE fluorescence intensity (MFI) of each
454 bead subset was exported to Excel. The MFI of beads coupled with viral antigens was
455 divided by that measured on beads coupled with neutravidin only (relative MFI, rMFI). A total
456 of 979 pre-pandemic sera and 810 sera from COVID-19 convalescents were analyzed to
457 establish cutoffs for seropositivity. A double cutoff of rMFI >5 for anti-RBD and anti-Spike FL
458 yielded a specificity of 99.7% and a sensitivity of 95% (53). Serum from an individual who
459 had received three doses of the Pfizer/BioNTech anti-COVID-19 vaccine was used as
460 standard to convert signals to binding antibody units per milliliter (BAU/ml).

461 Statistics and analysis

462 Statistical analyses were performed using GraphPad Prism v.9 for Windows, GraphPad
463 Software. Two-tailed p values are shown. For analysis of functional markers (CD40L+ TNF-
464 α + CD4 T cells and IFN- γ + TNF- α + CD8 T cells), data from FACS plots with fewer than 1000
465 CD4 or CD8 T cells were excluded.

466 Study approval

467 The study was approved by the Norwegian South-Eastern Regional Ethical Committee
468 (Reference numbers 200631, 235424, 135924, and 204104), and the Norwegian Medicines
469 Agency (EudraCT Number: 2021- 003618-37). All participants gave written informed consent
470 prior to inclusion in this study.

471

472 Author contributions

473 LAM and SM conceived and designed the study. A-SW drafted the paper. AR, MK, LAM, TH,
474 GON, and SM contributed to drafting the paper. A-SW, AR, GS, IFK, and AC performed
475 experiments. A-SW, AR, MK, GS, IFK, FL-J, GON, LAM, and SM analyzed and interpreted
476 data. MHØ, AC, TH, HFH, EAH, JTV, and EGC contributed to data analysis and
477 interpretation. MK, GON, MHØ, SWS, KKJ, JTV, FL-J, and LAM organized the collection of
478 samples and information from the cohorts. A-SW, AR and MK are joint first authors with the
479 order determined by contribution to experimental analysis and writing of the manuscript. All
480 authors contributed to and approved the final manuscript.

481

482 Acknowledgements

483 The authors would like to thank Ingrid Egner, Katrine Persgård Lund, Viktoriia Chaban, and
484 Julie Røkke Osen at the Department of Immunology, Oslo University Hospital for biobanking
485 and technical help. We would also like to thank the participants in the NevroVax study and
486 staff at Diakonhjemmet Hospital and Akershus University Hospital for donating blood
487 samples, as well as the staff at Oslo University Hospital for taking the samples. This study
488 was supported by the Norwegian Institute of Public Health, the Norwegian Ministry of Health
489 through a program for corona vaccination surveillance, the Odd Fellows Foundation, the
490 Sanofi Research Fund for MS, the Norwegian MS Society, and the Research Council of
491 Norway (RCN) Covid (312693), LAM, SM; a KG Jebsen Foundation (grant 19), LAM; the
492 Coalition for Epidemic Preparedness Innovations (CEPI), LAM, SM, JTV, FL-J; and the
493 University of Oslo and Oslo University Hospital, LAM, FL-J, JTV.

494 References

- 495 1. Brodin P. Immune determinants of COVID-19 disease presentation and severity. *Nat*
496 *Med.* 2021;27(1):28-33.
- 497 2. Kelly H, et al. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
498 *J Neuroimmunol.* 2021;356:577599.
- 499 3. Hada M, et al. Systematic review of risk of SARS-CoV-2 infection and severity of
500 COVID-19 with therapies approved to treat multiple sclerosis. *Neurol Sci.* 2022:1-11.
- 501 4. Sharifian-Dorche M, et al. COVID-19 and disease-modifying therapies in patients with
502 demyelinating diseases of the central nervous system: A systematic review. *Mult Scler Relat*
503 *Disord.* 2021;50:102800.
- 504 5. Centonze D, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in
505 multiple sclerosis: an expert consensus. *J Neurol.* 2021;268(11):3961-8.
- 506 6. Sormani MP, et al. Disease-Modifying Therapies and Coronavirus Disease 2019
507 Severity in Multiple Sclerosis. *Ann Neurol.* 2021;89(4):780-9.
- 508 7. Sormani MP, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy
509 and France. *Ann Clin Transl Neurol.* 2021;8(8):1738-44.
- 510 8. Salter A, et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in
511 a North American Registry of Patients With Multiple Sclerosis. *JAMA Neurol.* 2021;78(6):699-
512 708.
- 513 9. Luna G, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With
514 Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. *JAMA Neurol.*
515 2020;77(2):184-91.
- 516 10. Salzer J, et al. Rituximab in multiple sclerosis: A retrospective observational study on
517 safety and efficacy. *Neurology.* 2016;87(20):2074-81.
- 518 11. Zhao Z, et al. Incidence and Risk of Infection Associated With Fingolimod in Patients
519 With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12
520 Randomized Controlled Trials. *Front Immunol.* 2021;12.

- 521 12. Ghadiri F, et al. The study of COVID-19 infection following vaccination in patients with
522 multiple sclerosis. *Mult Scler Relat Disord.* 2022;57:103363.
- 523 13. Dreyer-Alster S, et al. COVID-19 vaccination in patients with multiple sclerosis: Safety
524 and humoral efficacy of the third booster dose. *J Neurol Sci.* 2022;434:120155.
- 525 14. Tallantyre EC, et al. COVID-19 Vaccine Response in People with Multiple Sclerosis.
526 *Ann Neurol.* 2022;91(1):89-100.
- 527 15. König M, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple
528 sclerosis: the relevance of time since last rituximab infusion and first experience from
529 sporadic revaccinations. *J Neurol Neurosurg Psychiatry.* 2021;jnnp-2021-327612.
- 530 16. Katz JD, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple
531 sclerosis patients treated with ocrelizumab. *Mult Scler Relat Disord.* 2022;57:103382.
- 532 17. Apostolidis SA, et al. Cellular and humoral immune responses following SARS-CoV-2
533 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med.*
534 2021;27(11):1990-2001.
- 535 18. Bar-Or A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple
536 sclerosis: The VELOCE study. *Neurology.* 2020;95(14):e1999-e2008.
- 537 19. Türkoğlu R, et al. Fingolimod impairs inactivated vaccine (CoronaVac)-induced
538 antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis. *Mult*
539 *Scler Relat Disord.* 2022;58:103524.
- 540 20. Altieri M, et al. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine
541 in people with multiple sclerosis treated with natalizumab. *Neurol Sci.* 2022.
- 542 21. Iannetta M, et al. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients
543 With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and
544 Clinical Implications. *Front Immunol.* 2021;12:796482.
- 545 22. Brill L, et al. Effect of cladribine on COVID-19 serology responses following two doses
546 of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. *Mult Scler Relat Disord.*
547 2022;57:103343.

- 548 23. Ciampi E, et al. Safety and humoral response rate of inactivated and mRNA vaccines
549 against SARS-CoV-2 in patients with Multiple Sclerosis. *Mult Scler Relat Disord*.
550 2022;59:103690.
- 551 24. Habek M, et al. Humoral and cellular immunity in convalescent and vaccinated
552 COVID-19 people with multiple sclerosis: Effects of disease modifying therapies. *Mult Scler*
553 *Relat Disord*. 2022;59:103682.
- 554 25. Sabatino JJ, Jr., et al. Multiple sclerosis therapies differentially impact SARS-CoV-2
555 vaccine-induced antibody and T cell immunity and function. *JCI Insight*. 2022.
- 556 26. Tortorella C, et al. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2
557 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
558 *Neurology*. 2022;98(5):e541-e54.
- 559 27. Gadani SP, et al. Discordant humoral and T cell immune responses to SARS-CoV-2
560 vaccination in people with multiple sclerosis on anti-CD20 therapy. *EBioMedicine*.
561 2021;73:103636.
- 562 28. Bajwa HM, et al. Persistently reduced humoral and sustained cellular immune
563 response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple
564 sclerosis patients. *Mult Scler Relat Disord*. 2022;60:103729.
- 565 29. König M, et al. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in
566 Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.
567 *JAMA Neurol*. 2022.
- 568 30. Brill L, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine
569 Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab. *Ann Neurol*.
570 2022;91(6):796-800.
- 571 31. Disanto G, et al. Association of disease-modifying treatment and anti-CD20 infusion
572 timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis.
573 *JAMA Neurol*. 2021;78(12):1529-31.
- 574 32. Brill L, et al. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients
575 With Multiple Sclerosis Treated With Ocrelizumab. *JAMA Neurol*. 2021;78(12):1510-4.

- 576 33. Brown JWL, et al. Association of Initial Disease-Modifying Therapy With Later
577 Conversion to Secondary Progressive Multiple Sclerosis. *JAMA*. 2019;321(2):175-87.
- 578 34. Spelman T, et al. Treatment Escalation vs Immediate Initiation of Highly Effective
579 Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different
580 National Strategies. *JAMA Neurol*. 2021;78(10):1197-204.
- 581 35. Norwegian Institute of Public Health. Coronavirus vaccination - statistics. 2022
582 [updated 01/08/2022. Available from: [https://www.fhi.no/en/id/vaccines/coronavirus-](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/coronavirus-vaccination---statistic/)
583 [immunisation-programme/coronavirus-vaccination---statistic/](https://www.fhi.no/en/id/vaccines/coronavirus-vaccination---statistic/).
- 584 36. Francis G, et al. Temporal profile of lymphocyte counts and relationship with
585 infections with fingolimod therapy. *Mult Scler*. 2014;20(4):471-80.
- 586 37. Sullivan R, et al. COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients:
587 Case series. *Neurol Neuroimmunol Neuroinflamm*. 2022;9(1):e1092.
- 588 38. Thomas K, et al. Fingolimod additionally acts as immunomodulator focused on the
589 innate immune system beyond its prominent effects on lymphocyte recirculation. *J*
590 *Neuroinflammation*. 2017;14(1):41.
- 591 39. Leon J, et al. A virus-specific monocyte inflammatory phenotype is induced by SARS-
592 CoV-2 at the immune-epithelial interface. *PNAS*. 2022;119(1):e2116853118.
- 593 40. McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple
594 sclerosis and other conditions. *Lancet*. 2021;398(10306):1184-94.
- 595 41. Garjani A, et al. Impact of mass vaccination on SARS-CoV-2 infections among
596 multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
597 *Mult Scler Relat Disord*. 2022;57:103458.
- 598 42. Schiavetti I, et al. Breakthrough SARS-CoV-2 infections in MS patients on disease-
599 modifying therapies. *Mult Scler*. 2022;0(0):13524585221102918.
- 600 43. Sormani MP, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA
601 vaccination in MS patients on disease modifying therapies during the Delta and the Omicron
602 waves in Italy. *EBioMedicine*. 2022;80:104042.

- 603 44. Bsteh G, et al. Impact of vaccination on COVID-19 outcome in multiple sclerosis. *Eur*
604 *J Neurol.* 2022.
- 605 45. Servellita V, et al. Neutralizing immunity in vaccine breakthrough infections from the
606 SARS-CoV-2 Omicron and Delta variants. *Cell.* 2022;185(9):1539-48.e5.
- 607 46. Yu ED, et al. Development of a T cell-based immunodiagnostic system to effectively
608 distinguish SARS-CoV-2 infection and COVID-19 vaccination status. *Cell Host Microbe.*
609 2022;30(3):388-99.e3.
- 610 47. Liu J, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2
611 Omicron. *Nature.* 2022;603(7901):493-6.
- 612 48. Swadling L, et al. Pre-existing polymerase-specific T cells expand in abortive
613 seronegative SARS-CoV-2. *Nature.* 2022;601(7891):110-7.
- 614 49. Earle KA, et al. Evidence for antibody as a protective correlate for COVID-19
615 vaccines. *Vaccine.* 2021;39(32):4423-8.
- 616 50. Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune
617 protection from symptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27(7):1205-11.
- 618 51. McMahan K, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques.
619 *Nature.* 2021;590(7847):630-4.
- 620 52. Tran TT, et al. Multiplexed measurement of binding-and neutralizing antibodies to
621 SARS- CoV-2 variants in 12.000 post-vaccine sera. *bioRxiv.* 2022.
- 622 53. Jyssum I, et al. Humoral and cellular immune responses to two and three doses of
623 SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective,
624 cohort study. *Lancet Rheumatol.* 2022;4(3):e177-e87.
- 625 54. Huang Y, et al. Structural and functional properties of SARS-CoV-2 spike protein:
626 potential antiviral drug development for COVID-19. *Acta Pharmacol Sin.* 2020;41(9):1141-9.
- 627

628 Figure legends

629 Table 1: Summary of participant characteristics. Participants are grouped by DMT. V0
630 indicates pre-vaccination baseline samples, V2 indicates samples taken after receiving 2
631 doses of vaccine, and V3 indicates samples taken after 3 doses of vaccine. Numbers of
632 individuals per DMT group, age, sex, time since last drug treatment, vaccine types, time
633 between sampling and the corresponding vaccine dose, and the number of participants in
634 each group who were subsequently infected with COVID-19 >2 weeks post-vaccination.

635

636 Figure 1: Lymphocyte proportions in peripheral blood and spike-specific vaccination
637 responses in pwMS on DMTs. Individuals are grouped by DMT (healthy controls (HC),
638 alemtuzumab (ALEM)-, cladribine (CLAD)-, natalizumab (NTZ)-, fingolimod (FIN)- and
639 rituximab (RTX)-treated MS patients). (A) CD3+ lymphocyte proportions and (B) the ratio of
640 CD4:CD8 T cells in different DMT groups showed reduced frequencies of CD3+ lymphocytes
641 and CD4+ T cells in fingolimod-treated patients. Violin plots show individuals as separate
642 points, lines indicate median, IQR, and min and max. Mann-Whitney test comparing drug-
643 treated groups with healthy controls, two-tailed p values were calculated, **** p<0.0001. (C)
644 Binding antibody units after 2 doses of vaccine. Responses below the lower limit of detection
645 are shown as 0.5 BAU/ml; titres <5 BAU/ml are considered negative, 5-20 BAU/ml as very
646 weak positives, 20-200 BAU/ml as weak positives and >200 BAU/ml as positives. (D) CD4 T
647 cell (CD40L+ TNF- α +) and (E) CD8 T cell responses (IFN- γ + and/or TNF- α +) to spike
648 peptides before (V0) and after (V2) 2 doses of vaccine. Responses with 0 events are plotted
649 at 0.001% to indicate non-responses. Samples from the same individual before and after
650 vaccination are paired with a line. Patient numbers for each group are indicated along the x-
651 axis. Individuals with <1000 CD4 or CD8 T cells acquired by FACS were excluded from
652 further analysis. Statistical comparisons by Wilcoxon two-tailed paired t-tests, * p<0.05.

653

654 Figure 2: T cell and antibody responses in rituximab- and fingolimod-treated patients after 3rd
655 vaccine dose. Antibody responses (BAU/ml), CD4+ and CD8+ T cell responses after 3rd
656 vaccine dose in rituximab-treated (A-C) and fingolimod-treated patients (D-F) (A, n=43-61);
657 B, n=21-56; C, n=21-54; D, n=13-21; E, n=6-13; F, n=6-17). Individuals with <1000 CD4+ T
658 cells acquired by FACS were excluded from this analysis. Dotted lines in (A) and (D) indicate
659 classification of antibody responses as negative or positive as described previously. For B-C
660 and E-F, lines on scatter plots indicate the median. Statistical analyses by Wilcoxon paired t-
661 tests, two-tailed p values are shown, * p<0.05, *** p<0.001

662

663 Figure 3: Re-administration of rituximab between vaccine doses affects antibody but not T
664 cell responses. Rituximab-treated individuals were grouped by whether or not they received
665 a dose of RTX between vaccine doses 2 and 3. (A) Antibody titres (BAU/ml) after 2nd (V2)
666 and 3rd (V3) vaccine doses for patients who did not receive RTX between vaccines (empty
667 boxes) (n= 20-32) and patients who did receive RTX between vaccines (grey boxes) (n=23-
668 30). (B) CD4 T cell and (C) CD8 T cell responses without stimulation (unstim) or to SARS-
669 CoV-2 spike or CMV peptides after 3rd vaccine dose for patients without (n=28) or with RTX
670 administration (n=28) between vaccine doses, as previously. Statistical analyses for paired
671 responses by Wilcoxon t test, unpaired responses by Mann-Whitney, two-tailed p values are
672 shown, * p<0.05, ** p<0.01.

673

674 Figure 4: T cell responses to the Delta and Omicron SARS-CoV-2 variants after three
675 vaccine doses. Schematic of mutated regions in the Alpha, Delta and Omicron regions
676 stimulated by peptides (A). The SARS-CoV-2 spike protein is 1273 amino acids (aa) long,
677 consisting of the signal peptide, S1 and S2 subunits; the receptor binding domain (RBD) in
678 S1 is indicated in red (54). Regions covered by the SARS-CoV-2 Prot_S (WT) peptide used
679 for AIM assays are shown for reference. The control and mutant peptides for each variant

680 cover the same loci but with the mutated (mutant) or Wuhan-Hu-1 variant (control). Amino
681 acid mutations are listed in Methods. PBMCs from rituximab-treated patients after a 3rd
682 vaccine dose were stimulated with spike peptide pools from the mutated regions (blue
683 circles) of the Alpha (n=29), Delta (n=41) and Omicron VOC (n=21) and the same regions of
684 the WT sequence (empty circles) and the CD4+ (B) and CD8+ (C) T cell responses were
685 compared. Statistical differences were calculated by Wilcoxon paired t tests. * p<0.05, **
686 p<0.01





		Alemtuzumab		Cladribine		Natalizumab		Fingolimod			Rituximab			Healthy controls	
		V0	V2	V0	V2	V0	V2	V0	V2	V3	V0	V2	V3	V0	V2
n		11	11	8	8	10	8	12	18	20	5	13	63	15	15
Previous COVID-19 infection (%)		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (80.0)	5 (38.5)	3 (4.8)	0	0
Age (years)	Median	37.4	37.4	42.4	42.4	37.0	37.0	41.8	45.3	47.7	29.6	39.1	43.3	46	46
	Mean	35.3	35.3	41.5	41.5	38.1	37.8	41.1	45.1	47.0	31.1	41.1	46.0	46.0	46.0
	Range	22 - 47.5	22 - 47.5	34.0 - 47.3	34.0 - 47.3	26.3 - 51.6	26.3 - 51.6	33.1 - 49.0	33.1 - 60.4	30.5 - 66.0	18.3 - 47.3	18.3 - 76.9	22.1 - 76.9	25.0 - 63.0	25.0 - 63.0
Sex	Female (%)	8 (72.7)	8 (72.7)	8 (100)	8 (100)	7 (70.0)	6 (75.0)	6 (50.0)	8 (44.4)	11 (55.0)	3 (60.0)	9 (69.2)	53 (84.1)	12 (80.0)	12 (80.0)
Time since last drug treatment (weeks)	Median	164.1	165.9	31.3	32.5	0	0.93				5.86	14.5	24.7/8.43 ^b		
	Mean	156.2	157.9	36.2	38.9	-1.7 ^a	1.89				9.37	18.5	28.1/8.31 ^b		
	Range	70.3 - 252.1	71.7 - 252.4	3.0 - 78.4	5.14 - 83.4	-4.57 - 5.14 ^a	0.29 - 6.0	Taken daily			-0.7 - 31.9 ^a	8.43 - 46.0	17.0 - 63.0/1.86 - 19.7 ^b	n/a	n/a
Vaccine type - first dose (n)	BNT162b2		9		6		6		12	14		7	52 ^d		0
	mRNA-1273		2		2		2		6	6		3	8		9
	ChAdOx1-S		0		0		0		0	0		0	3		6
	COVID-19 infection		0		0		0		0	0	4	3 ^c	2 ^d		0
Vaccine type - second dose (n)	BNT162b2		9		6		6		12	14		10	55		6
	mRNA-1273		2		2		2		6	6		3	8		9
Vaccine type - third dose (n)	BNT162b2									6			12		
	mRNA-1273	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	14	n/a	n/a	51	n/a	n/a
Time between sample and last vaccine dose (days)	Median		11		12		12		13	28.5		38	23		10
	Mean		11.2		19.4		13.9		22.6	29.3		33.5	25.6		10.3
	Range	n/a	8 - 15	n/a	7 - 73	n/a	9 - 26	n/a	7 - 49	20 - 43	n/a	8 - 71	20 - 42	n/a	8 - 16
Covid infection >14 days post-full vaccination (%)		n/a	2 (18.2)	n/a	3 (37.5)	n/a	3 (37.5)	n/a	n/a	2 (10.0)	n/a	n/a	14 (22.2)	n/a	5 (33.3)

^a Negative time values indicate drug was administered after sample was taken

^b Individuals are split into groups who last received RTX prior to V0 and those who received RTX between V2 and V3 (see Fig. 3)

^c Some individuals were infected with COVID-19 at baseline, which was treated as analogous to a first vaccine dose

^d Some individuals with prior COVID-19 infections still received a 'first' vaccine dose of BNT162b2 and are represented twice

A**B****C****D****E**